Merck & Co., Inc. (MRK)[Tv]

Key Developments

• FDA Accelerated Approval of KEYTRUDA + Padcev for Neoadjuvant/Adjuvant Muscle-Invasive Bladder Cancer – The FDA’s approval of Merck’s KEYTRUDA in combination with Pfizer’s Padcev marks a transformative milestone as the first and only PD-1 inhibitor/ADC regimen approved for this indication regardless of cisplatin eligibility, unlocking a vast, underserved patient population and reinforcing Merck’s leadership in immuno-oncology.

• $6.7 Billion Acquisition of Terns Pharmaceutical – Merck’s strategic purchase of Terns, a company with advanced oncology assets including TERN-701, significantly strengthens its long-term innovation runway and signals a decisive pivot from Keytruda dependency toward next-generation pipeline development.

• FDA Approval of KEYTRUDA + Trodelvy for First-Line PD-L1-Positive Triple-Negative Breast Cancer – This approval expands Keytruda’s footprint into a high-unmet-need indication, delivering a differentiated, high-value treatment with minimal competition, and positioning Merck to capture substantial market share in a growing oncology segment.